Soufflé Therapeutics

souffletx.com →

-56%

est. 2Y upside i

HealthcareSeries A

Rank

#1041

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Medium

Soufflé Therapeutics presents a high-risk, high-reward equity opportunity.

Last updated: March 10, 2026

Bull (35%)+300%

Successful clinical trials for lead programs in FSHD and cardiomyopathies validate Soufflé's cell-specific delivery platform, which addresses a long-standing challenge in drug development. This success attracts new major pharma partnerships and enables a Series B/C round at a $800M-$1B+ valuation, demonstrating significant de-risking and market leadership potential.

Base (25%)+50%

Soufflé makes steady progress in preclinical and early clinical development, securing additional milestone payments from existing partnerships with companies like Bayer, AbbVie, Amgen, and Novo Nordisk. The company raises another funding round at a modest valuation increase to ~$300M, reflecting incremental de-risking but facing continued long development timelines and competitive pressures.

Bear (40%)-80%

Clinical setbacks, unexpected safety concerns, or the emergence of superior competing delivery technologies from well-funded incumbents like Alnylam or CRISPR Therapeutics lead to a failure to secure further funding or a down round. The valuation drops significantly, wiping out most common stock value due to the $200M liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

100%

Investors hold $200M in liquidation preferences, equal to the current valuation. In an exit at or below $200M, common stock holders would likely receive little to nothing.

Dilution Risk

high

As a clinical-stage Series A company with very high capital intensity, Soufflé will require significant additional funding rounds, leading to substantial future dilution for existing shareholders.

Secondary Liquidity

none

As an early-stage private company, there is currently no active secondary market for Soufflé Therapeutics equity.

Questions to Ask at the Interview

Strategic questions based on Soufflé Therapeutics's data — designed to show you've done your homework.

  • 1

    “Given the highly competitive landscape in siRNA and genetic medicines, how does Soufflé plan to maintain its strong competitive moat against established players like Alnylam and emerging technologies from CRISPR Therapeutics?”

  • 2

    “With lead programs entering clinical trials in 2026, what are the key milestones and data readouts the company is prioritizing over the next 18-24 months, and how will success in these areas translate into future funding and partnership opportunities?”

  • 3

    “Considering the $200M in liquidation preferences on the current $200M valuation, what is the company's strategy for creating significant value for common stock holders, and what is the anticipated timeline for a potential liquidity event?”

Community

Valuation Sentiment

Our model estimates -56% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.